Letter to the editor in re: Mohan et al., 2020 'dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels'.
| Autor: | Romach EH; Viiv Healthcare, RTP, NC, USA. Electronic address: beth.h.romach@viivhealthcare.com., Posobiec LM; GlaxoSmithKline, Collegeville, PA, USA., Bloomer JC; GlaxoSmithKline, Ware, UK., Zamek-Gliszczynski MJ; GlaxoSmithKline, Collegeville, PA, USA., Stanislaus DJ; GlaxoSmithKline, Collegeville, PA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | EBioMedicine [EBioMedicine] 2021 Apr; Vol. 66, pp. 103335. Date of Electronic Publication: 2021 Apr 12. |
| DOI: | 10.1016/j.ebiom.2021.103335 |
| Abstrakt: | Competing Interests: Declaration of Competing Interest Authors are employees of Viiv Healthcare (EHR) and GlaxoSmithKline (LMP, JCB, MJZ, DJS). There are no conflicts of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|